This real-world cohort study evaluated outcomes in 36 patients with alopecia areata who switched from deuruxolitinib to baricitinib, examining the reasons for switching and hair regrowth responses after transition.
Specific response rates and absolute outcome numbers are not available from the provided abstract, but the study reports real-world hair regrowth outcomes in 36 patients following the JAK inhibitor switch.
Small cohort of only 36 patients limits generalizability; real-world design without a control arm; potential for confounding by indication given switching was likely driven by clinical or access factors.
For patients with alopecia areata who cannot continue deuruxolitinib, switching to baricitinib may be a viable option; this real-world data can help guide shared decision-making when JAK inhibitor transitions are needed.
